Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning
Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.
Edwards celebrates double-digit TAVR sales growth in Q4
It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry.
Stroke risk after TAVR still higher for woman as ‘sex paradox’ lives on
By tracking sex-related differences after TAVR, researchers hope to refine patient selection strategies and optimize care for both men and women.
TAVR valve for AR , a recent Edwards acquisition, delivers long-term value
The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.
SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves
Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

heart data research doctor cardiologist AI

Post-TAVR echocardiography helps predict a patient’s long-term risk of SVD

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.

Abbott’s Navitor TAVR valve linked to positive real-world outcomes

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

TAVR’s next big challenge: Providing consistent relief for heart patients with aortic regurgitation

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?

Low-volume operators linked to worse outcomes after TAVR, M-TEER

Researchers tracked data from more than 400,00 patients, sharing their findings in JAMA Cardiology.

Haemonetics acquires Irish medtech company focused on vessel closure for up to $215M

The device at the heart of this transaction is the PerQseal Elite system, a fully bioabsorbable patch for percutaneous vessel closure. The technology has already gained key approvals in Europe.

court judge gavel business man bankruptcy lawsuit

Judge blocks Edwards’ JenaValve acquisition—FTC calls it a ‘major win’ for Trump administration

The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed.

TAVR, other interventional procedures may provide value for patients with carcinoid heart disease

These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.

Structural Heart Disease

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Edwards celebrates double-digit TAVR sales growth in Q4

Stroke risk after TAVR still higher for woman as ‘sex paradox’ lives on

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value

SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves